Generalized pustular psoriasis
Information
- Disease name
- Generalized pustular psoriasis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05366855 | Active, not recruiting | Phase 3 | Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis | April 21, 2022 | December 2026 |
| NCT03886246 | Active, not recruiting | Phase 2 | Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study | May 27, 2019 | January 20, 2028 |
| NCT03942042 | Completed | Phase 4 | A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis | July 5, 2019 | July 22, 2020 |
| NCT04399837 | Completed | Phase 2 | A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis | June 4, 2020 | November 23, 2022 |
| NCT05200247 | Completed | Phase 3 | An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | February 17, 2022 | March 20, 2023 |
| NCT05239039 | Completed | Phase 3 | An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | March 15, 2022 | July 17, 2023 |
| NCT05352893 | Completed | Phase 3 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | April 14, 2022 | August 17, 2023 |
| NCT03619902 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis | January 30, 2019 | January 20, 2021 |
| NCT03782792 | Completed | Phase 2 | Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis | January 31, 2019 | January 5, 2021 |
| NCT05512598 | Completed | Phase 1 | HB0034 in Patients With Generalized Pustular Psoriasis (GPP) | November 6, 2022 | January 10, 2024 |
| NCT06391996 | Completed | Biologic Therapy for Generalized Pustular Psoriasis | July 1, 2019 | December 30, 2023 | |
| NCT06433531 | Not yet recruiting | Phase 1 | A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) | June 2024 | February 2025 |
| NCT06013969 | Recruiting | Phase 4 | A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares | October 11, 2023 | April 8, 2027 |
| NCT06100991 | Recruiting | CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry | September 19, 2023 | December 2099 | |
| NCT05670821 | Recruiting | PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms | March 29, 2023 | December 31, 2025 | |
| NCT06323356 | Recruiting | Phase 3 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | March 19, 2024 | March 27, 2026 |
| NCT06295692 | Recruiting | Phase 3 | A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | February 9, 2024 | December 23, 2027 |
| NCT04566471 | Unknown status | Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence | January 1, 2012 | December 31, 2021 |
- OrphaNumber from OrphaNet (Orphanet)
- 247353
- ICD10 preferred id (Insert disease from ICD10)
- D0009752
- ICD10 class code (Insert disease from ICD10)
- L40.1